Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P03950

UPID:
ANGI_HUMAN

ALTERNATIVE NAMES:
Ribonuclease 5

ALTERNATIVE UPACC:
P03950; Q05CV1; Q53X86; Q6P5T2; Q8WXE7

BACKGROUND:
Angiogenin functions as a ribonuclease that targets tRNA, generating fragments that play a key role in the cellular response to stress by inhibiting protein synthesis and promoting stress granule formation. Its ability to bind to actin and induce vascularization highlights its critical role in tissue development and response to injury. Angiogenin's regulatory interaction with RNH1 further illustrates its complex role in angiogenesis and cellular stress mechanisms.

THERAPEUTIC SIGNIFICANCE:
The association of angiogenin with Amyotrophic Lateral Sclerosis 9 underscores its potential as a therapeutic target. By delving into the intricate functions of angiogenin, researchers can uncover new avenues for treating ALS9, offering hope for interventions that could significantly impact patient outcomes in this fatal neurodegenerative condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.